Liquid Biopsies in Renal Cell Carcinoma-Recent Advances and Promising New Technologies for the Early Detection of Metastatic Disease.
liquid biopsy
prognostic markers
renal cell carcinoma (RCC)
translational research
tumor biomarkers
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
07
2020
accepted:
29
09
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
17
11
2020
Statut:
epublish
Résumé
Clear cell renal cell carcinoma (ccRCC) displays a highly varying clinical progression, from slow growing localized tumors to very aggressive metastatic disease (mRCC). Almost a third of all patients with ccRCC show metastatic dissemination at presentation while another third develop metastasis during the course of the disease. Survival rates of mRCC patients remain low despite the development of novel targeted treatment regimens. Biomarkers indicating disease progression could help to define its aggressive potential and thus guide patient management. However, molecular markers that can reliably assess metastatic dissemination and disease recurrence in ccRCC have not been recommended for clinical practice to date. Liquid biopsies could provide an attractive and non-invasive method to determine the risk of recurrence or metastatic dissemination during follow-up and thus assist the search for surveillance biomarkers in ccRCC tumors. A wide spectrum of circulating molecules have already shown considerable potential for ccRCC diagnosis and prognostication. In this review, we outline state of the art of the key circulating analytes such as cfDNA, cfRNA, proteins, and exosomes that may serve as biomarkers for the longitudinal monitoring of ccRCC progression to metastasis. Moreover, we address some of the prevailing limitations in the past approaches and present promising adoptable technologies that could help to pursue the implementation of liquid biopsies as a prognostic tool for mRCC.
Identifiants
pubmed: 33194717
doi: 10.3389/fonc.2020.582843
pmc: PMC7656014
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
582843Informations de copyright
Copyright © 2020 Lakshminarayanan, Rutishauser, Schraml, Moch and Bolck.
Références
Can Urol Assoc J. 2016 Mar-Apr;10(3-4):113-9
pubmed: 27217858
J Enzyme Inhib Med Chem. 2018 Dec;33(1):234-240
pubmed: 29251173
Micromachines (Basel). 2018 Jun 15;9(6):
pubmed: 30424233
Urol Oncol. 2017 May;35(5):294-299
pubmed: 28089386
Eur Urol. 2017 Oct;72(4):557-564
pubmed: 28413127
Cancers (Basel). 2019 Sep 30;11(10):
pubmed: 31575051
BMC Urol. 2020 Feb 4;20(1):7
pubmed: 32013938
Clin Genitourin Cancer. 2020 Aug;18(4):322-331.e2
pubmed: 32046920
Biomed Res Int. 2015;2015:802153
pubmed: 26425554
Exp Mol Pathol. 2013 Feb;94(1):115-20
pubmed: 23064048
Theranostics. 2020 Jan 16;10(5):2374-2384
pubmed: 32089746
Oncotarget. 2014 Jan 30;5(2):506-18
pubmed: 24504108
Nat Cell Biol. 2011 Apr;13(4):423-33
pubmed: 21423178
Mol Med Rep. 2019 Dec;20(6):5075-5083
pubmed: 31661117
Mol Clin Oncol. 2013 Jan;1(1):69-74
pubmed: 24649125
Int Urol Nephrol. 2020 Mar;52(3):437-446
pubmed: 31732842
Eur Urol Focus. 2018 Apr;4(3):412-419
pubmed: 28753793
Clin Proteomics. 2020 Jul 29;17:28
pubmed: 32742246
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8
pubmed: 21383194
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Mol Cell Proteomics. 2018 Nov;17(11):2284-2296
pubmed: 30104208
Genome Med. 2020 Feb 28;12(1):23
pubmed: 32111235
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Oncotarget. 2017 Jun 13;8(41):69551-69558
pubmed: 29050224
Acta Oncol. 2018 Apr;57(4):498-508
pubmed: 29095068
Clin Cancer Res. 2018 Nov 15;24(22):5594-5601
pubmed: 30037816
Clin Chim Acta. 2016 Jan 15;452:109-19
pubmed: 26569345
Oncotarget. 2018 Apr 17;9(29):20467-20475
pubmed: 29755665
J Immunother Cancer. 2019 Nov 29;7(1):334
pubmed: 31783776
Ann Transl Med. 2017 Feb;5(3):46
pubmed: 28251125
Cancer Lett. 2017 May 28;394:1-12
pubmed: 28089832
Clin Genet. 2019 Jun;95(6):643-660
pubmed: 30671931
J Proteome Res. 2020 Jul 2;19(7):2563-2574
pubmed: 32396726
Nat Med. 2020 Jul;26(7):1114-1124
pubmed: 32483360
J Clin Oncol. 2018 Jun 1;36(16):1631-1641
pubmed: 29504847
Eur Urol Focus. 2019 Jun 29;:
pubmed: 31266731
Cell. 2018 Apr 19;173(3):595-610.e11
pubmed: 29656894
Oncotarget. 2017 Jul 22;8(38):63703-63714
pubmed: 28969022
Cell. 2007 Feb 23;128(4):683-92
pubmed: 17320506
Exp Mol Pathol. 2017 Apr;102(2):255-261
pubmed: 28214514
J Immunother Cancer. 2019 Nov 27;7(1):325
pubmed: 31775882
Sci Transl Med. 2019 Aug 28;11(507):
pubmed: 31462507
Proteomics. 2003 Dec;3(12):2310-6
pubmed: 14673781
EBioMedicine. 2018 Jun;32:111-118
pubmed: 29807833
Cell Rep. 2018 Apr 3;23(1):313-326.e5
pubmed: 29617669
Urol Int. 2013;91(3):273-8
pubmed: 23860338
Indian J Biochem Biophys. 2010 Aug;47(4):211-8
pubmed: 21174948
BJU Int. 2007 Feb;99(2):296-300
pubmed: 17326263
Mol Cell Proteomics. 2019 Jun;18(6):1242-1254
pubmed: 30948622
J Proteome Res. 2018 Nov 2;17(11):3877-3888
pubmed: 30260228
Int J Cancer. 2019 Jul 15;145(2):531-539
pubmed: 30650187
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
J Transl Med. 2018 Jan 9;16(1):1
pubmed: 29316942
Cell. 2018 Apr 19;173(3):581-594.e12
pubmed: 29656895
Anticancer Res. 2010 Jul;30(7):2785-9
pubmed: 20683013
Cell. 2016 Jan 14;164(1-2):57-68
pubmed: 26771485
Mol Biosyst. 2013 Jun;9(6):1220-33
pubmed: 23511837
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
Cancer Sci. 2019 Feb;110(2):617-628
pubmed: 30536551
Bull Exp Biol Med. 2019 Jul;167(3):388-392
pubmed: 31346876
Urology. 2010 Feb;75(2):262-5
pubmed: 19962739
J Thorac Dis. 2018 Apr;10(Suppl 7):S882-S897
pubmed: 29780635
J Urol. 2005 Oct;174(4 Pt 1):1213-7
pubmed: 16145372
J Am Soc Nephrol. 2005 Apr;16(4):1126-34
pubmed: 15744000
Oncotarget. 2016 Nov 29;7(48):78433-78447
pubmed: 27738339
Tumour Biol. 2014 May;35(5):4057-66
pubmed: 24379138
Eur Urol Focus. 2016 Jun;2(2):210-218
pubmed: 28723537
Am J Transl Res. 2019 Mar 15;11(3):1219-1229
pubmed: 30972157
J Thorac Oncol. 2016 Oct;11(10):1690-700
pubmed: 27468937
Neoplasia. 2019 Feb;21(2):247-256
pubmed: 30660076
J Proteomics. 2019 Jan 16;191:29-37
pubmed: 29689304
Cancer Cell. 2016 May 9;29(5):653-668
pubmed: 27117758
Ann Oncol. 2019 May 1;30(5):706-720
pubmed: 30788497
Cell. 2018 Apr 19;173(3):611-623.e17
pubmed: 29656891
Int J Cancer. 2018 Feb 1;142(3):607-617
pubmed: 28975613
Ann Surg Oncol. 2014 Mar;21(3):1046-54
pubmed: 24242678
Cancer Res. 2005 Jun 1;65(11):4817-26
pubmed: 15930302
Nucleic Acids Res. 2010 Nov;38(20):7248-59
pubmed: 20615901
Genet Med. 2020 Aug;22(8):1366-1373
pubmed: 32341571
Arch Med Sci. 2019 May;15(3):738-753
pubmed: 31110542
Clin Epigenetics. 2018 Jan 23;10:11
pubmed: 29410711
PLoS One. 2014 Nov 04;9(11):e111364
pubmed: 25368985
Clin Cancer Res. 2015 Feb 15;21(4):889-98
pubmed: 25691774
Br J Cancer. 2011 Nov 22;105(11):1741-9
pubmed: 22033272
Int J Cancer. 2020 Jul 19;:
pubmed: 32683679
PLoS One. 2014 May 09;9(5):e96094
pubmed: 24816817
Kidney Cancer. 2017 Jul 26;1(1):65-70
pubmed: 30334006
Exp Biol Med (Maywood). 2017 Jun;242(11):1136-1141
pubmed: 28485684
Oncogenesis. 2016 Feb 15;5:e192
pubmed: 26878386
Cancers (Basel). 2019 Dec 19;12(1):
pubmed: 31861557